24/7 Wall St. screened the Stifel specialty pharmaceutical list and found five stock rated Buy that have massive upside potential and probably don’t have the investment risk of some of the more speculative biotech…
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.
We screened our 24/7 Wall St. research database for hot biotech ideas and found four companies that are offering big upside for aggressive accounts. All are rated Buy and have the potential to provide…
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study…
Atara Biotherapeutics shares surged on Friday after the firm announced that it received clearance from the FDA to initiate two Phase 3 clinical studies.
Progenics Pharmaceuticals saw its shares make a solid gain to close out the year after the FDA accepted for review the firm’s New Drug Application (NDA) for Azedra.
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech stocks increased.
Although Shire is not seeing much of a bump in its share price, the firm is creating a lot of value with its most recent submission to the FDA.
Teva Pharmaceutical saw its shares make a small gain on Wednesday after the firm announced the exclusive launch of a generic version of Reyataz capsules in the United States.
Mallinckrodt has seen its shares rise on news that it was acquiring Sucampo Pharmaceuticals for roughly $840 million.
